bioAffinity Technologies, Inc. (BIAF) NASDAQ
2.12
+1.05(+98.13%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.12
+1.05(+98.13%)
Currency In USD
Address
22211 West Interstate 10
San Antonio, TX 78257
United States of America (the)
Phone
210 698 5334
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
57
First IPO Date
September 01, 2022
| Name | Title | Pay | Year Born |
| Maria Zannes | Founder, President, Chief Executive Officer & Director | 327,157 | 1956 |
| Steven Girgenti | Founder & Executive Chairman of the Board | 115,430 | 1946 |
| James Michael Edwards | Chief Financial Officer | 139,213 | 1967 |
| Gordon Downie | Chief Medical Officer | 0 | N/A |
| William Bauta | Chief Science Officer | 0 | N/A |
| Dallas J. Coleman | Vice President of sales | 0 | N/A |
| Timothy Zannes | Executive VP, Secretary & General Counsel | 0 | 1953 |
| Xavier T. Reveles | Chief Operating Officer | 0 | 1970 |
| Julie Anne Overton | Director of Communications | 0 | N/A |
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.